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Hsaio and colleagues link gutmicrobes to autism spectrumdisorders (ASD) in amousemodel. They
show that ASD symptoms are triggered by compositional and structural shifts of microbes and
associated metabolites, but symptoms are relieved by a Bacteroides fragilis probiotic. Thus probi-
otics may provide therapeutic strategies for neurodevelopmental disorders.Rapid advances in analytical and
sequencing technologies have spurred a
renaissance of research into connections
between the microbial communities that
inhabit our gut and physiological condi-
tions. Given the complexity of gut micro-
bial communities, estimated to contain
500–1,000 species that considerably
expand our metabolic potential beyond
what the human genome encodes, it
is perhaps unsurprising that they can
influence many aspects of our physi-
ology and gut-linked health and disease.
For example, TLR5 knockout mice can
become obese because an altered micro-
bial community, instead of affectingmeta-
bolic efficiency, increases its appetite
(Vijay-Kumar et al., 2010), or in a mouse
model of multiple sclerosis, demyelination
only occurs in the context of the gut
microbiota (Lee et al., 2011, Berer et al.,
2011). In addition, microbial impacts on
neurology are also evident, including anx-
iety and sociability in mice (Collins et al.,
2013) and changing emotions in humans
who received fermented milk with probi-
otics (Tillisch et al., 2013). In this issue of
Cell, Hsaio et al. (2013) make a striking
contribution to our understanding of the
influence of gut bacteria using an animal
model that replicates autism-like behav-
iors in mouse offspring following maternal
immune activation (Figure 1). They show
that microbial shifts within the gut of a
mouse resulted in changes of metabolites1446 Cell 155, December 19, 2013 ª2013 Elsin the serum and that these lead to
the onset of autism-like behaviors. More-
over, administering a beneficial bacte-
rium, Bacteroides fragilis, reversed the
physiological, neurological, and immuno-
logical anomalies.
Autism diagnoses have increased
rapidly over the last decade (currently 1
in 88 births, versus 1 in 150 reported
in 2000; http://www.cdc.gov/ncbddd/
autism/data.html), but no clear relation-
ships between genetic factors and ASD
symptoms have yet been found. How-
ever, gastrointestinal ASD symptoms
suggest a potential breakdown in normal
symbiotic relationships between the
host and its microbes (a dysbiosis), which
may affect health via systemic as well as
direct pathways, including immune sys-
tem interactions. In some ASD cases,
gut barrier integrity is reduced, increasing
permeability. This condition, together with
maternal immune activation (MIA), can
increase the abundance of certain bacte-
rial metabolites in the serum of offspring,
which if aberrant could influence
host behavior. Although current literature
regarding microbiota associated with
ASD patients is limited and contradictory,
there is evidence that ASD patients lack
certain beneficial bacteria in their gut,
e.g., Prevotella (Kang et al., 2013).
To bring these issues into sharper focus
in an experimentally tractable system,
Hsaio and colleagues used the MIA para-evier Inc.digm to model autism-like behaviors
in mice. In this animal model, pregnant
mice were injected with an immunos-
timulant, polyinosinic:polycytidylic acid
(poly(I:C)), which mimics a viral infection.
MIA results in offspring with ASD-like
behavioral symptoms and neuropa-
thology. They showed that this mouse
model for MIA reduced intestinal integrity
through altered gut bacterial community.
In offspring with reduced gut barrier integ-
rity, the authors identified 8% of as-
sayed bacterial metabolites that differed
significantly in abundance compared to
those with intact gut barrier function.
When the MIA offspring mice were fed
with Bacteroides fragilis, a gut microbe
with positive effects on the immune sys-
tem, the abundance of 34% of these me-
tabolites changed back, gut barrier integ-
rity was improved, the gut-microbiome
was restored to a state similar to control
mice, and a number of ASD-related
behavioral abnormalities were amelio-
rated. In addition, a 46-fold increase of
4-ethylphenylsulfate (4EPS) in the serum
of MIA offspring returned to normal levels.
The authors demonstrated the gut
bacteria may generate 4EPS by showing
that germ-free mice have undetectable
serum concentrations of 4EPS. Interest-
ingly, 4EPS accumulates in patients
with chronic renal failure and is related
to p-cresol, which is present in urine of
children with ASD and is suggested as a
Figure 1. Evolution of a Pipeline for Therapeutic Strategies for Neurodevelopmental Disor-
ders Based on Microbiome and Metabolite Profiling
Top: Experiments using mouse models (for example, an MIA mouse with symptoms of ASD and
potentially other behavioral disorders) and subsequent community profiling can provide a mechanistic
understanding of the importance of specific gut microbes and their metabolites in triggering the illness
process, especially when lead compounds or microbes are applied to germ-free mice. Middle: Potential
treatments to restore the healthy state of the mouse model (replacements of the identified missing
microbes and/or the differences in metabolites they cause) can be tested and validated in preclinical
trials, including different strategies for altering the microbial community and/or metabolite profile. For
example, introducing a beneficial microbe such as the probiotic strains of B. fragilis used by Hsaio et al.
may decrease a harmful metabolite rather than increasing a beneficial one. Bottom: Formulation
and application of analogous treatments in human trials may lead to new ways to treat the behavioral
and physiological problems associated with human neurodevelopmental disorders. Careful clinical trials
will be needed in humans, as the effects of a given microbe and metabolite may differ in different
species.human autism biomarker (Persico and
Napolioni, 2013), although additional
studies would be needed to confirm the
generality of this finding. Coincidently,
the MIA mice in this study had p-cresol
in their serum, but it was not at significant
levels. When the authors added synthetic
4EPS to wild-type mice, they induced
anxiety-like behavior similar to that
observed in MIA mice. A second metabo-
lite elevated in the MIA serum, and
normalized by treatment with B. fragilis,
was indolepyruvate. Indolepyruvate is
generated by microbial tryptophan
catabolism and is related to indolyl-3-acryloylglycine, another human autism
marker. Indolepyruvate elevation could
be linked to increased serum levels of
serotonin, yet another human autism
biomarker. Application of the B. fragilis
probiotic increased many other metabo-
lites, including N-acetylserine, which the
authors hypothesize may provide protec-
tion against some ASD symptoms.
This groundbreaking study provides
some of the first conclusive evidence of
the impact of MIA on GI tract integrity
that is reversible via administration of a
specific probiotic. It also shows that a
suite of metabolic markers is generatedCell 155, Deby bacteria, altered in dysbiosis, and
normalized by probiotic treatment. Impor-
tantly, the authors demonstrate that
elements of the MIA phenotype can be
caused by a specific microbial metabo-
lite. This is an excellent example of
how a combination of bacterial commu-
nity profiling, mouse models, germ-free
mice, and metabolomics can be used to
mechanistically understand the effects of
the gut microbiome on health and disease
states and to develop therapeutic strate-
gies to treat key conditions.
The broader potential of this research
is obviously an analogous probiotic that
could treat subsets of individuals with
ASD. The observation that 4EPS imparts
anxiety-like symptoms in normal mice
suggests that other neurodevelopmental
illnesses may also be linked to microbial
metabolites in serum. If probiotics, such
as B. fragilis that ameliorate ‘bad’ metab-
olites along with their negative neurolog-
ical consequences could be identified
in relevant mouse models, the implica-
tions for the mental health of humans
are extraordinary. MIA has been linked
to a range of human conditions, including
depression and schizophrenia (Knight
et al., 2007), and several reports indicate
that probiotics can treat anxiety and
posttraumatic stress disorder (PTSD) in
mouse models, including one model that
requires an intact vagus nerve for gut-
brain signaling (Bravo et al., 2011). Thera-
pies that target our microbial side may
hold the key to making progress against
a wide range of notoriously difficult psy-
chiatric illnesses.
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TET-mediated 5-methyl cytosine (5mC) oxidation acts in epigenetic regulation, stem cell
development, and cancer. Hu et al. nowdetermine the crystal structure of the TET2 catalytic domain
bound to DNA, shedding light on 5mC-DNA substrate recognition and the catalytic mechanism of
5mC oxidation.Substantial amounts of 5-hydroxymethyl
cytosine (5hmC) have been observed in
murine embryonic stem cells and brain.
The three ten-eleven translocation
(TET1-3) proteins have been identified to
act as 2-oxoglutarate (2-OG)- and Fe(II)-
dependent dioxygenases to catalyze the
oxidation of 5mC to 5hmC. TET dioxyge-
nases can further oxidize 5hmC to
5-formylcytosine (5fC) and 5-carboxycy-
tosine (5caC) in genomic DNA. 5caC can
then be recognized by thymine DNA
glycosylase in DNA demethylation pro-
cesses (Kohli and Zhang, 2013). In this
issue, Hu et al. (2013) determine the crys-
tal structure of the TET2-DNA complex to
elucidate how TET dioxygenases may
mediate 5mC oxidation and the impact
of TET2 clinical mutations.
Most missense TET2 mutations are in
the catalytic domain. Hu et al. show that
clinical mutations found in human cancers
decrease catalytic activity by affecting the
5mC recognition, DNA interaction, and
2-OG/Fe(II) interactions in vitro and in vivo.
Frequent mutations of TET2 in leukemia
suggest that TET2 helps to regulate he-matopoiesis and that mutations impact
cancer development. Although multiple
mutations may be needed to cause the
clinical phenotype (Delhommeau et al.,
2009), the TET2 structural analysis helps
to define the connection between these
mutations and disease phenotypes.
TET13 share similar catalytic activities
and conserved C-terminal catalytic
domains, which contain a Cys-rich region
and double-strand b helix (DSBH)
domain. The structure of TET2 catalytic
domain with dsDNA reveals 5mC-DNA
substrate recognition with bound Fe(II)
and N-oxalylglycine (NOG, a 2-OG
analog). The interesting intramolecular
interaction of Cys-rich and DSBH
domains includes an unexpected domain
swap between these domains. This
feature helps to create a unique holder
for DNA substrate recognition, in which
both the Cys-rich and DSBH domains
bind DNA.
Only two other 2-OG-dependent
dioxygenase-DNA complex structures,
human ABH2 and E. coli AlkB, have
been previously known. Human ABH2dioxygenase can repair by oxidative de-
methylation several different methylated
DNA modifications (1mA, 3mC, 1mG,
and 3mT) (Yi et al., 2012). Due to the insta-
bility of base pairing, the methylated base
is flipped out. ABH2 uses Phe102 to
probe the base lesion on DNA, and
Phe102 intercalates into the duplex stack
to ensure that the methyl group is posi-
tioned in the catalytic cavity (Figure 1A)
(Yang et al., 2008). According to this
tipping mechanism (Figure 1A), the
Phe102 tip constantly probes for base-
pair instability as DNA slides through
the ABH2 protein. Similarly, TET2 dioxy-
genase uses Tyr1294 to probe for
base-pair instability, and this residue in-
tercalates into the duplex stack when a
methylated cytosine is found. Mutation
of Tyr1294 results in decreased activity.
Hu et al. show that there is no binding
difference between 5mCpG-DNA and
5CpG-DNA, implying that the methyl
group does not impact DNA binding.
TET2 seems unlikely to discriminate
5hmC, 5fC, and 5caC in the active
site as long as the 5mC derivatives
